







A REVIEW OF HLA AND COVID-19 ASSOCIATION STUDIES 
Renata Zunec  
 
Abstract: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), is reported to vary across different populations in the prevalence of infection, in the death rate of patients, in the 
severity of symptoms and in the drug response of patients. Among host genetic factors that can influence all these 
attributes human leukocyte antigen (HLA) genetic system stands out as one of the leading candidates. Case-control 
studies, large-scale population-based studies, as well as experimental bioinformatics studies are of utmost importance to 
confirm HLA susceptibility spectrum of COVID-19. This review presents the results of the first case-control and 
epidemiological studies performed in several populations, early after the pandemic breakout. The results are pointing to 
several susceptible and protective HLA alleles and haplotypes associations with COVID-19, some of which might be of 
interest for the future studies in Croatia, due to its common presence in the population. However, further multiple 
investigations from around the world, as numerous as possible, are needed to confirm or deteriorate these preliminary 
results. 
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INTRODUCTION 
Coronavirus disease 2019 (COVID-19), an infectious 
viral disease caused by Severe Acute Respiratory 
Syndrome Coronavirus-2 (SARS-CoV-2), pandemic is 
now affecting all countries of the world, with more than 
50 000 000 people infected and with more than 1 000 
000 deaths, as of the 15th of November 2020. The 
incidence, morbidity and mortality data for each country 
can be followed at the daily updated web page 
https://www.arcgis.com/apps/opsdashboard/index.html
#/bda7594740fd40299423467b48e9ecf6 (Coronavirus 
COVID-19 global cases by the centre for systems 
science and engineering at Johns Hopkins University). 
As for any other viral disease, susceptibility or resilience 
to SARS-CoV-2 infection arises through the complex 
interaction of comorbid statuses, environment 
backgrounds and host genetic factors. 
The host genetic factors have influence on disease 
susceptibility and disease severity, can help identify 
individuals who are at risk for disease, might affect 
pharmacokinetics and pharmacodynamics of drugs used 
in COVID-19 patients, can help altering the treatment 




ROLE OF HLA SYSTEM 
The human major histocompatibility complex, the 
human leukocyte antigen (HLA), stands out as one of 
the leading genetic factor candidates that might play an 
eminent role in COVID‐19 susceptibility, severity, and 
outcomes as well as in geographical variation. 
HLA system is a genomic region in the chromosomal 
position 6p21 composed of at least 132 protein coding 
genes and the similar number of non-coding genes that 
have important roles in the regulation of the immune 
system. Evolution of its structural organization involved 
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rearrangement events over the period of 500 million 
years.1 
The HLA system spans approximately 4,200 kilobases 
of DNA. The HLA genes, which primary role is to 
encode diverse antigen-presenting molecules, are 
divided into three classes, class I, II and III. The class I 
region, includes 19 gene loci among which three are 
classical loci HLA-A, HLA-B and HLA-C, three non-
classical and twelve non-coding genes or pseudogenes. 
The class II region includes the classical gene loci HLA-
DP, HLA-DQ, and HLA-DR, the non-classical HLA-
DO and HLA-DM loci and a group of genes outside the 
MHC whose functions are related to antigen 
presentation: large multifunctional protease (LMP) and 
transporter associated with antigen processing (TAP) 
genes. HLA-DR loci involves a single DRA gene and up 
to nine DRB genes (DRB1 to DRB9). The DRA gene 
encodes an invariable α chain which binds various β 
chains encoded by the DRB genes. HLA-DR molecules 
are determined by the polymorphic DRβ1 chains 
encoded by DRB1 alleles. The HLA-DP and -DQ loci 
each have one expressed gene for α and β chains and 
additional unexpressed pseudogenes. The DQA1 and 
DQB1 gene products associate to form DQ molecules, 
and the DPA1 and DPB1 gene products form DP 
molecules. 
The HLA class III region lies between the class I and 
class II genes and contains genes with varying functions, 
among which are the genes for the complement proteins 
C4A, C4B, C2 and factor B and genes for tumor necrosis 
factor (TNF) and heatshock protein 70 (HSP70).2 
Alongside its key role in the transplantation medicine, 
HLA is likewise of great interest to the clinical 
medicine, as an important factor for understanding the 
pathogenesis of various diseases, from autoimmune 
diseases to bacterial and viral infection diseases. 
Namely, an effective host response against all viruses 
depend on HLA-restricted T-lymphocyte responses.  
HLA molecules, encoded by HLA class I and HLA class 
II genes, are cell-surface glycoproteins that present 
intracellular and extracellular peptides to T cells. In the 
case of viral infection, viral epitopes are presented by 
dendritic cells to CD8+ T lymphocytes through HLA 
class I molecules and through HLA class II molecules to 
CD4+ T lymphocytes (Figure 1). Presentation through 
HLA class I molecules primes to the clonal expansion of 
HLA-restricted CD8+ cytotoxic T lymphocytes (CTLs). 
Efficacious antiviral defense during acute infection is 
mainly dependent on CTLs response while memory 
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CD4+ T lymphocytes enhance CTLs responses and 
provide T-cell help to the generation of specific antiviral 
antibodies. Consequently, through their central role in 
viral antigen presentation HLA molecules act as a 
marker for genetic susceptibility to infectious disease.4 
Thus, since the outbreak of (COVID-19), HLA genes 
came into the focus as a potential marker for the disease 
susceptibility and severity. HLA region is the most 
polymorphic genetic system in the human genome, 
which numbered more than 28 000 class I and class II 
alleles included in the IPD-IMGT/HLA Database at the 
end of October 2020.5, 6 
In order to emphasize this extensive level of 
polymorphism, the term hyper-polymorphic, instead of 
simple polymorphic, has been introduced.7 
The main advantage of such hyper-polymorphism is the 
large potential of the heterozygosity in the population. 
In comparison to homozygous individuals, 
heterozygous individuals are capable of presenting a 
larger variety of peptides which leads to the better 
protection against pathogens and consequently to the 
better capability to reproduce and survive. Indeed, 
worldwide studies of HLA allele frequencies 
distribution revealed around 90% heterozygosity at each 
HLA locus.8, 9 
Conversely to the evolutionary advantage, HLA hyper-
polymorphism is the main obstacle in disease 
association studies. Among thousands of HLA alleles, 
limited number of them are very common and common 
in the populations, whereas the vast majority belongs to 
the group of rare and vary rare alleles. Moreover, other 
HLA genetic characteristics, such as linkage 
disequilibrium which denotes that certain alleles occur 
together with a greater frequency than would be 
expected by chance and limitations in sample-size of 
patients and healthy controls which can lead to in-
sufficient power of statistical tests, are making disease 
association studies very puzzling in determining 
whether an allele or multiple alleles confer risk or 
protection to the pathogen. 
 
 
CASE- ⁠CONTROL STUDIES 
Although the outbreak of the SARS-CoV-2 pandemic 
now lasts for less than a year, several association studies 
have already been published, pointing to the possible 
HLA markers conferring either risk or protection to 
COVID-19.  
Since COVID-19 first broke out in Wuhan, Hubei 
province, China in late December 2019, the first study 
came, as expectedly, from China. Wang et al studied 11 
HLA loci allele frequencies in 82 confirmed COVID-19 
Han patients from Zhejiang by next generation 
sequencing (NGS). Two alleles, HLA‐C*07:29 and 
B*15:27 were more frequent in patients and the 
difference to the control group was found significant 
after P‐value correction. Several other alleles were 
found either with increased (B*40:06, C*08:01G, 
DRB1*04:06, DPB1*36:01) or decreased 
(DRB1*12:02 and DPB1*04:01) frequency in patients 
but the difference did not remain significant after the 
correction.10 
Another paper published on HLA genotypes in Chinese 
patients from Wuhan is a work by Warren and Birol who 
instead of performing the HLA typing, derived HLA 
types directly from metatranscriptomic RNA-Seq 
libraries using HLAminer. Libraries were prepared from 
bronchoalveolar lavage fluid and peripheral blood 
mononuclear cell samples of 8 COVID-19 patients at the 
early stage of the outbreak in Wuhan, China. The results 
indicated  the presence of HLA-A*24:02 allele  and 
class II DPA1*02:02-DPB1*05:01 haplotype in four 
and seven out of eight patients, respectively.11 
In Spain, country which was also highly affected during 
the first wave of COVID-19 pandemic, Iturrieta-Zuazo 
et al performed the pilot study aiming to analyze the 
association between HLA and the severity of the 
COVID-19. The patient group, which included a total of 
45 Spanish patients from Madrid with mild (N=5), 
moderate (N=20) and severe (N=29) SARS-CoV-2 
infection, was typed for HLA-A, -B and -C gene 
polymorphisms by PCR Sequence Specific 
Oligonucleotide reverse (SSO) method through 
Luminex technology. Allele frequencies of the Spanish 
healthy population were obtained from Allele 
Frequency Net Database using for each allele the 
average of the frequencies in all Spanish studies 
uploaded on this website. The analyses of HLA class I 
gene/allele frequencies was performed at the level of 
HLA supertypes. 
The results showed that the HLA alleles belonging to A2 
supertype (A*02:01, A*02:05, A*68:01, A*68:02) and 
to C1 supertype (C*01:02, C*03:03, C*03:04, C*07:01, 
C*07:02, C*08:01, C*08:02, C*12:02, C*12:03, 
C*16:01) were present with decreased frequencies in a 
severe group compared to moderate group and healthy 
controls, but without statistical significance. The finding 
was in concordance with the theoretical model of higher 
degree of recognition of SARS CoV-2 peptides for these 
two supertypes. Furthermore, the authors reported the 
association of the severe course of the disease with a 
higher percentage of homozygosity at HLA-A and –C 
locus in comparison with moderate one (20% vs. 10% in 
locus A, 15% vs. 5% in locus C) but no statistically 
significant differences were obtained. Interestingly, for 
locus HLA-B homozygosity was 5%, in both groups, 
and no homozygous was found among 5 mild patients. 
Based on these results, the authors suggest that the HLA 
heterozygosity and HLA molecules with a higher 
theoretical capacity for binding SARS-Cov-2 peptides 
are more present in patients with mild evolution of the 
COVID-19 than in patients with moderate and severe 
ones.12 
The first study on COVID-19 and HLA association in 
Italy was published by Novelli et al in August 2020. 
They investigated HLA allele frequency distribution at 
11 loci (HLA-A, B, C, DRB1, DRB3/4/5, DQA1, 
DQB1, DPA1, DPB1) typed by NGS method in a group 
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Legend: N - number of COVID-19 diagnosed patients included in the study; a - corresponding frequencies in the Croatian population are provided in 
order to show possible interest for the future association studies in Croatia, data obtained from reference 21 (number of individuals included in study 
n=10000),  b - data obtained  from reference  22 (n=124);  c - data obtained from  reference 23  (n=210);  NA - not applicable, epidemiological study; 




which lost the significance after the correction as well as 
the decreased frequency of C*06:02 and DRB1*07:01.13 
Two other Italian groups used geographical ecological 
approach to investigate the HLA and COVID-19 
association. The epidemiological study was performed 
severe form of COVID‐19. Control group consisted of 
1017 individuals. Increased frequencies in patients 
compared   to controls   which   remained significant 
after   the correction   were found   for   HLA‐B*27:07, 
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also revealed increased frequency found for B*58:01 by 
assessing the degree of correlation between the 
incidence and mortality of COVID-19 and the 
prevalence of HLA alleles in a healthy population. Both 
groups used HLA allele and haplotype frequencies from 
the database of the Italian Bone Marrow Donor Registry 
and compared the regional differences with the COVID-
19 incidence and mortality. Correale et al analyzed the 
role of HLA class I alleles (HLA-A, -B, -C) while 
Pisanti et al examined the role of the two most frequent 
HLA haplotypes in the Italian population. The results 
showed that HLA-B*44 and/or C*01, alleles are risk 
factors for SARS-CoV-2 infection, but the correlation 
with the morbidity and mortality was not observed. The 
positive correlation with the disease incidence was also 
observed for HLA-A*25, HLA-B*08 B*15:01, B*51, 
and C*03, as well as negative one for HLA-B*14, B*18, 
and B*49 alleles, but, after examination with multiple 
regression model, did not maintain independent and 
positive association with COVID-19 incidence. Number 
one haplotype by the frequency in the Italian population, 
HLA-A*01:01g~B*08:01g~C*07:01g~DRB1*03:01g, 
showed the positive correlation, while conversely, 
HLA-A*02:01g~B*18:01g~C*07:01g~DRB1*11:04g, 
which is the second most common haplotype, showed a 
negative correlation with COVID-19 incidence and 
mortality.14, 15 
Single center study performed by Luo et al at Memorial 
Sloan Kettering Cancer Center, New York, examined 
patient-specific and cancer-specific features that impact 
the severity of COVID-19 in lung cancer patients. One 
of the factor studied was the association of HLA-A and 
HLA-B alleles in a cohort of 46 patients, 29 with mild 
disease and 17 with severe disease compared with the 
control group of 5166 patients with lung cancers and no 
known COVID-19. The only difference observed was 
for HLA-B44 supertype which was more frequent 
among patients with severe COVID-19 but without 




CONCLUSIONS AND FUTURE DIRECTIONS 
The main limitation of all case-control studies presented 
in this review is small sample size of the patient groups 
with consequently questionable power of the statistical 
analysis.  
Moreover, the majority of HLA alleles found to be 
protective or susceptibility markers for COVID-19 in 
studied population so far, belong to rare or very rare 
HLA polymorphisms in other geographic regions of the 
world reflecting varying frequencies of HLA alleles and 
haplotypes across populations. The Croatian population 
has been extensively studied for the HLA allele and 
haplotype polymorphisms17 providing the database for 
further COVID-19 association studies in the Croatian 
cohort of patients. The frequencies of so far reported 
COVID-19 associated HLA specificities in the studies 
presented in this review, together with their frequencies 
in the Croatian population, are presented in Table 1. 
Results show that several alleles reported as COVID-19 
associated factors are represented in the Croatian 
population as common alleles and thus are of interest for 
further investigations, as well as it is the relationship 
between COVID-19 prevalence, severity and mortality 
with the observed regional differences of the HLA allele 
and haplotype distribution in Croatia (Grubic, submitted 
for publication). In any case, studies from other 
populations, as numerous as possible, are needed as an 
effort to take the global population stratification into 
account. 
Meanwhile, together with classical HLA disease 
association population studies, another kind of approach 
developed. These are the bioinformatics and 
experimental studies18, 19, 20 which so far identified and 
provided shortlist of SARS-CoV-2 derived peptides to 
bind several HLA class I and HLA class II molecules 
(HLA-A*02:01,   HLA-A*01:01,   HLA-B*07:02, 
HLA-C*07:02, HLA-B*40:01, HLA-DRA*01:01, 
HLA-DRB1*07:01 and HLA-DRB1*04:01), with some 
of them already confirmed in case-control studies (e.g. 
A2 supertype). However, the immunogenicity of these 
epitopes remains to be tested with the integration of 
HLA population studies and, if successful, can, amongst 
other evidence, provide crucial information for vaccine 
design. 
Further immunogenetic studies are expected to solve the 
HLA part of host genetic puzzle of SARS-CoV-2 
pandemic and to bring benefit to individual patients, to 
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